https://pubmed.ncbi.nlm.nih.gov/38091052

This study explores the optimum number of rituximab doses for children with Burkitt lymphoma based on different risk groups and develops a nomogram to predict overall survival. No significant difference in treatment outcomes was observed between four and six doses of rituximab